Masoumeh Fardi

Ms. Masoumeh Fardi

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Genes & Diseases
Verified
Journal Article
Open access
MFMasoumeh Fardi
Masoumeh Fardi
SSSaeed Solali
Saeed Solali
MHMajid Farshdousti Hagh
Majid Farshdousti Hagh
Epigenetic, along with genetic mechanisms, is essential for natural evolution and maintenance of specific patterns of gene expression in mammalians. Global epigenetic variation is inherited somatically and unlike genetic variation, it is dynamic and reversible. They are somatically associated with known genetic variations. Recent studies indicate the broad role of epigenetic mechanisms in the initiation and development of cancers, that they are including DNA methylation, histone modifications, nucleosomes changes, non-coding RNAs. The reversible nature of epigenetic changes has led to the emergence of novel epigenetic therapeutic approaches, so that several types of these medications have been approved by the FDA so far. In this review, we discuss the concept of epigenetic changes in diseases, especially cancers, the role of these changes in the onset and progression of cancers and the potential of using this knowledge in designing novel therapeutic strategies.

17 February 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MFMasoumeh Fardi
Masoumeh Fardi
MAMohammadreza Alivand
Mohammadreza Alivand
Behzad BaradaranBehzad Baradaran
Behzad Baradaran
MHMajid Farshdousti Hagh
Majid Farshdousti Hagh
SSSaeed Solali
Saeed Solali

9 February 2021 in Molecules
Verified
Journal Article
Open access
PDF file
SSSaeed Solali
Saeed Solali
MFMasoumeh Fardi
Masoumeh Fardi
NHNima Hemmat
Nima Hemmat
NKneda khosravi
neda khosravi
ADAfshin Derakhshani
Afshin Derakhshani
Behzad BaradaranBehzad Baradaran
Behzad Baradaran
Background: Glioma is an aggressive type of brain tumor that originated from neuroglia cells, accounts for about 80% of all malignant brain tumors. Glioma aggressiveness has been associated with extreme cell proliferation, invasion of malignant cells, and resistance to chemotherapies. Due to resistance to common therapies, glioma affected patients’ survival has not been remarkably improved. ZEB2 (SIP1) is a critical transcriptional regulator with various functions during embryonic development and wound healing that has abnormal expression in different malignancies, including brain tumors. ZEB2 overexpression in brain tumors is attributed to an unfavorable state of the malignancy. Therefore, we aimed to investigate some functions of ZEB2 in two different glioblastoma U87 and U373 cell lines. Methods: In this study, we investigated the effect of ZEB2 knocking down on the apoptosis, cell cycle, cytotoxicity, scratch test of the two malignant brain tumor cell lines U87 and U373. Besides, we investigated possible proteins and microRNA, SMAD2, SMAD5, and miR-214, which interact with ZEB2 via in situ analysis. Then we evaluated candidate gene expression after ZEB2-specific knocking down. Results: We found that ZEB2 suppression induced apoptosis in U87 and U373 cell lines. Besides, it had cytotoxic effects on both cell lines and reduced cell migration. Cell cycle analysis showed cell cycle arrest in G0/G1 and apoptosis induction in U87 and U373 cell lines receptively. Also, we have found that SAMAD2/5 expression was reduced after ZEB2-siRNA transfection and miR-214 upregulated after transfection. Conclusions: In line with previous investigations, our results indicated a critical oncogenic role for ZEB2 overexpression in brain glioma tumors. These properties make ZEB2 an essential molecule for further studies in the treatment of glioma cancer.

11 December 2019 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
KMKobra Shojaei Moghadam
Kobra Shojaei Moghadam
MHMajid Farshdousti Hagh
Majid Farshdousti Hagh
MAMohammad Reza Alivand
Mohammad Reza Alivand
MFMasoumeh Fardi
Masoumeh Fardi
AMAli Akbar Movassaghpour
Ali Akbar Movassaghpour
SSSaeed Solali
Saeed Solali
Purpose: Sepantronium bromide (YM155) is a Survivin inhibitor which recently advanced as an anticancer agent in phase II clinical trials. Survivin belongs to IAP (inhibitor of apoptosis) gene family and is a pivotal target for treatment due to its overexpression and oncogenic function in many malignancies, including acute lymphoblastic leukemia (ALL). Although survivin is a specific target for YM155, recent reports have shown that it has many other crucial targets that regulate its anti-apoptotic effects. The aim of this study was to investigate whether YM155 could have an effect on cell death-inducing genes as well as inducing apoptosis in T-ALL MOLT4- cell line. Methods: We treated MOLT-4 cells with increasing concentrations of YM155 and then cell viability was determined using MTT (methyl thiazolyl tetrazolium) assay. Also, the rate of induction of apoptosis in MOLT-4 cells and the target genes expression levels were evaluated by Annexin V/PI and real-time PCR, respectively. Results: YM155 inhibited cell growth in MOLT-4 cells. This outcome is achieved by inducing apoptosis and a significant increase in the expression level of P53, MiR-9, caspase 3 and decreasing the mRNA expression levels of survivin, Sirtuin1(SIRT1), member of anti-apoptotic proteins family (Bcl-2), and epithelial-to-mesenchymal transition (EMT) initiating factors Snail1and Zeb2. Conclusion: The results showed that use of YM155 can be a potential drug therapy in T-ALL patients with promising effects on apoptosis induction.

1 April 2021 in Current Gene Therapy
Verified
Journal Article
Closed access
PDF file
MFMasoumeh Fardi
Masoumeh Fardi
AMAli Mohammadi
Ali Mohammadi
BBBehzad Baradaran
Behzad Baradaran
SSSahar Safaee
Sahar Safaee
SSSaeed Solali
Saeed Solali
Introduction:: Acute myeloid leukemia (AML) is the most prevalent type of cancer in the adult hematopoietic system. Conventional therapies are associated with unfavorable side effects in individuals diagnosed with AML. These after-effects with partial remission reflect the urgent need for novel therapeutic approaches for inducing apoptosis, specifically in malignant cells, without affecting other cells. As a transcription factor (TF), ZEB2 (Zinc Finger E-Box Binding Homeobox 2) regulates the expression of specific genes in normal conditions. However, increased expression of ZEB2 is reported in various cancers, especially in AML, which is related to a higher degree of apoptosis inhibition of malignant cells. In this work, the role of ZEB2 in apoptosis inhibition is surveyed through ZEB2 specific knocking-down in human myeloid leukemia HL-60 cells. Materials and Methods:: Transfection of HL-60 cells was conducted using ZEB2-siRNA at concentrations of 20, 40, 60, and 80 pmol within 24, 48, and 72 h. After determining the optimum dose and time, flow cytometry was used to measure the apoptosis rate. The MTT assay was also utilized to evaluate the cytotoxic impact of transfection on the cells. The expression of candidate genes was measured before and after transfection using qRT-PCR. Results:: According to obtained results, suppression of ZEB2 expression through siRNA was associated with the induction of apoptosis, increased pro-apoptotic, and decreased anti-apoptotic gene expression. Transfection of ZEB2-siRNA was also associated with reduced cell proliferation and viability. Conclusion:: Our study results suggest that ZEB2 suppression in myeloid leukemia cells through apoptosis induction could be a proper therapeutic method.

4 August 2026 in Molecules
Verified
Journal Article
Open access
PDF file
SSSaeed Solali
Saeed Solali
MFMasoumeh Fardi
Masoumeh Fardi
NHNima Hemmat
Nima Hemmat
NKneda khosravi
neda khosravi
ADAfshin Derakhshani
Afshin Derakhshani
Behzad BaradaranBehzad Baradaran
Behzad Baradaran
The journal retracts the article entitled “Silencing ZEB2 induces apoptosis and reduces viability in glioblastoma cell lines”